Investment Analysts’ Weekly Ratings Changes for BioCryst Pharmaceuticals (BCRX)

BioCryst Pharmaceuticals (NASDAQ: BCRX) recently received a number of ratings updates from brokerages and research firms:

• 9/10/2026 – BioCryst Pharmaceuticals was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $11.00 price target on the stock, down from $13.00.
• 9/8/2026 – BioCryst Pharmaceuticals had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $16.00 price target on the stock.
• 8/29/2026 – BioCryst Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/27/2026 – BioCryst Pharmaceuticals had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 8/8/2026 – BioCryst Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 8/6/2026 – BioCryst Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $14.00 to $13.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – BioCryst Pharmaceuticals had its price target lowered by Wedbush from $21.00 to $20.00. They now have an “outperform” rating on the stock.

BioCryst Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes orally administered medicines for rare diseases. The company focuses on treatments that address significant unmet medical needs, using expertise in small-molecule drug discovery and development.

BioCryst’s primary commercial product is ORLADEYO (berotralstat), an oral, once-daily medication used to prevent hereditary angioedema attacks in adults and pediatric patients ages 12 and older.